Cellular and Ionic Mechanisms Underlying Effects of Cilostazol, Milrinone and Isoproterenol to Suppress Arrhythmogenesis in an Experimental Model of Early Repolarization Syndrome by Patocskai, Bence et al.
See	discussions,	stats,	and	author	profiles	for	this	publication	at:	https://www.researchgate.net/publication/291953956
Cellular	and	Ionic	Mechanisms	Underlying
Effects	of	Cilostazol,	Milrinone	and
Isoproterenol	to	Suppress	Arrhythmogenesis	in
an	Experimental	Model	of	Early	Repolarization
Syndrome
Article		in		Heart	rhythm:	the	official	journal	of	the	Heart	Rhythm	Society	·	January	2016
Impact	Factor:	5.08	·	DOI:	10.1016/j.hrthm.2016.01.024
READS
44
6	authors,	including:
Hector	Barajas	Martinez
Masonic	Medical	Research	Laboratory
58	PUBLICATIONS			1,048	CITATIONS			
SEE	PROFILE
Dan	Hu
Masonic	Medical	Research	Laboratory
73	PUBLICATIONS			1,120	CITATIONS			
SEE	PROFILE
Istvan	Koncz
University	of	Szeged
22	PUBLICATIONS			310	CITATIONS			
SEE	PROFILE
Charles	Antzelevitch
Lankenau	Institute	for	Medical	Research
531	PUBLICATIONS			34,931	CITATIONS			
SEE	PROFILE
All	in-text	references	underlined	in	blue	are	linked	to	publications	on	ResearchGate,
letting	you	access	and	read	them	immediately.
Available	from:	Charles	Antzelevitch
Retrieved	on:	06	May	2016
Author's Accepted Manuscript
Cellular and Ionic Mechanisms Underlying Effects
of Cilostazol, Milrinone and Isoproterenol to Sup-
press Arrhythmogenesis in an Experimental Model
of Early Repolarization Syndrome
Bence Patocskai MD, Hector Barajas-Martinez PhD,
FHRS, Dan Hu MD, PhD, FHRS, Zsolt Gurabi MD,
István Koncz MD, PhD, Charles Antzelevitch PhD,
FHRS
PII: S1547-5271(16)00124-7
DOI: http://dx.doi.org/10.1016/j.hrthm.2016.01.024
Reference: HRTHM6604
To appear in: Heart Rhythm
Cite this article as: Bence Patocskai MD, Hector Barajas-Martinez PhD, FHRS, Dan Hu
MD, PhD, FHRS, Zsolt Gurabi MD, István Koncz MD, PhD, Charles Antzelevitch PhD,
FHRS, Cellular and Ionic Mechanisms Underlying Effects of Cilostazol, Milrinone and
Isoproterenol to Suppress Arrhythmogenesis in an Experimental Model of Early
Repolarization Syndrome, Heart Rhythm, http://dx.doi.org/10.1016/j.hrthm.2016.01.024
This is a PDF file of an unedited manuscript that has been accepted for publication. As a
service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting galley proof
before it is published in its final citable form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply
to the journal pertain.
www.elsevier.com/locate/buildenv
Cellular and Ionic Mechanisms Underlying Effects of Cilostazol, Milrinone 
and Isoproterenol to Suppress Arrhythmogenesis in an Experimental 
Model of Early Repolarization Syndrome 
 
 
Bence Patocskai, MD
a, b
; Hector Barajas-Martinez, PhD, FHRS
a
; Dan Hu MD, PhD, FHRS
a
; 
Zsolt Gurabi MD
a,b
; István Koncz, MD, PhD
a, b;
 Charles Antzelevitch, PhD, FHRS
 c
 
 
a
Masonic Medical Research Laboratory, 2150 Bleecker Street, Utica, NY 13501, USA; 
b
Department of Pharmacology & Pharmacotherapy, University of Szeged, Dóm Square 12, 
Szeged 6721 , Hungary; 
c
Lankenau Institute for Medical Research, 100 East Lancaster Ave, 
Wynnewood, PA 19096, USA 
 
 
Running title:  Patocskai: Suppression of arrhythmogenesis in ERS models 
 
Address for correspondence: 
    Charles Antzelevitch, PhD, FAHA, FHRS, FACC 
Lankenau Institute for Medical Research 
100 East Lancaster Ave 
 Wynnewood, PA 19096, USA 
Phone:  (315) 725-1390 
E-mail:  cantzelevitcch@gmail.com 
 
and  
 
Hector Barajas-Martinez, MSc, PhD, FHRS. 
Clinical Director, Molecular Genetics Department 
Research Scientist II/Experimental Cardiology 
Masonic Medical Research Laboratory 
2150 Bleecker Street 
Utica, NY 13501-1787 
Tel: (315) 735-2217 ext. 120 
Fax: (315) 735-5648 
E-mail: barajash@mmrl.edu 
 
Phone:  (315) 725-1390 
Total word count: 5,008    
Funding sources: This study was supported by grant HL47678 from NHLBI (CA) and a 
postdoctoral fellowship grant from the Heart Rhythm Society (IK) 
Disclosures: None. 
 
2 
 
 
 
ABSTRACT 
Background: Early Repolarization Syndrome (ERS) is associated with polymorphic ventricular 
tachycardia (PVT) and fibrillation (VF), leading to sudden cardiac death.  
Objective: The present study tests the hypothesis that the Ito-blocking effect of 
phosphodiesterase-3 (PDE-3) inhibitors plays a role in reversing repolarization heterogeneities 
responsible for arrhythmogenesis in experimental models of ERS. 
Methods: Transmembrane action potentials (AP) were simultaneously recorded from epicardial 
and endocardial regions of coronary-perfused canine left-ventricular (LV) wedge preparations, 
together with a transmural pseudo-ECG. The Ito-agonist NS5806 (7-15 μM) and ICa-blocker 
verapamil (2-3 uM) were used to induce an ER pattern and PVT.  
Results: Following stable induction of arrhythmogenesis, the PDE-3 inhibitors cilostazol and 
milrinone or isoproterenol were added to the coronary perfusate. All were effective in restoring 
the AP dome in the LV epicardium, thus abolishing the repolarization defects responsible for 
phase-2-reentry (P2R) and PVT. Arrhythmic activity was suppressed in 7/8 preparations by 
cilostazol (10 µM), 6/7 by milrinone (2.5 µM) and 7/8 by isoproterenol (0.1-1µM).  Using 
voltage clamp techniques applied to LV epicardial myocytes, both cilostazol (10 M) and 
milrinone (2.5 µM) were found to reduce Ito by 44.4% and 40.4%, respectively, in addition to 
their known effects to augment ICa.  
Conclusions: Our findings suggest that PDE-3 inhibitors exert an ameliorative effect in the 
setting of ERS by producing an inward shift in the balance of current in the early phases of the 
3 
 
epicardial AP via inhibition of Ito as well as augmentation of ICa, thus reversing the repolarization 
defects underlying development of P2R and VT/VF.  
Key words: Phosphodiesterase-3 inhibitors, Transient outward potassium current, Pharmacology, 
Ventricular fibrillation, Sudden Cardiac Death, Electrophysiology, Early Repolarization 
Abbreviations: 
AMI: acute myocardial infarction 
AP: transmembrane action potential 
APD: action potential duration 
ATP: adenosine-triphosphate 
cAMP: cyclic adenosine-monophosphate 
ECG: electrocardiogram 
EDR: epicardial dispersion of repolarization 
Endo: endocardium/ endocardial 
Epi: epicardium/epicardial 
ER: early repolarization 
ERP: early repolarization pattern  
ERS: early repolarization syndrome 
ICa: L-type calcium current 
IK-ATP: ATP-sensitive potassium current 
INa: cardiac voltage-gated fast sodium current  
Ito: transient outward current 
Jp: peak of the J wave (or the onset of end-QRS slur) 
LV: left ventricle 
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P2R: phase 2 reentry 
PDE-3: phosphodiesterase-3 
PKA: protein kinase A (cAMP-dependent protein kinase) 
(P)VT: (polymorphic) ventricular tachycardia 
RV: right ventricle 
SCD: sudden cardiac death 
TDR: transmural dispersion of repolarization 
VF: ventricular fibrillation 
 
INTRODUCTION: 
Early Repolarization Syndrome (ERS) has attracted a great deal of attention because of 
its association with sudden cardiac death (SCD) secondary to development of malignant 
arrhythmias.
1, 2
 Case-control and population-based studies point to an association of ER with the 
development of ventricular tachycardia (VT) and fibrillation (VF) in select individuals. ER 
pattern (ERP) in the ECG is characterized by a J point elevation ≥ 0.1mV manifesting as a notch 
or slur on the final 50% of the downslope of the QRS (J wave). 
1-5
. According to the most recent 
consensus reports by Macfarlane et al., J point is to be measured at the peak of the end-QRS 
notch or the onset of the end-QRS slur, labelled as Jp. Early case-controlled studies by 
Haïssaguerre and co-workers, Nam and co-workers and Rosso and co-workers reported an ERP 
in the ECGs of 31-60 % of their patients presenting with idiopathic ventricular fibrillation
6-8
. 
More recent studies report association of ERP with a higher risk for development of arrhythmias 
during acute myocardial infarction (AMI)
9
 and therapeutic hypothermia
10, 11
. 
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Recent studies from our group have provided evidence in support of the hypothesis that 
ERS is caused by a preferential accentuation of the AP notch in the LV epicardium secondary to 
an outward shift in the balance of current contributing to the early phases of the action 
potential.
4, 12
 Higher intrinsic levels of Ito were shown to account for the greater sensitivity of the 
inferior LV wall to development of VT/VF in the setting or ERS.
4
 The outward shift in the 
balance of currents was attributable to mutations in genes causing a gain of function in IK-ATP 
(KCNJ8 and ABCC9) or Ito (KCNE5 mutation and rare polymorphism in DPP10) 
13-17
 or loss of 
function in ICa (CACNA1C, CACNB2 and CACNA2D1)
18, 19
 or INa (SCN5A and SCN10A).
20, 21
 
The goal of a pharmacologic approach to therapy should therefore be to produce an inward shift 
in the balance of current flowing during the early phases of the LV epicardial AP.  
In previous studies, we demonstrated that induction of mild ER by an outward shift in the 
balance of current during the early phases of the AP could potentiate the effect of hypothermia to 
induce VT and that a pharmacologic-induced inward shift of current, using PDE-3 inhibitors or 
Ito block with quinidine, exerts an ameliorative effect.
12
 The present study provides a direct test 
of the hypothesis that both PDE-3 inhibitors reduce Ito, significantly contributing to their 
ameliorative effect in J wave syndromes. We examine the effects of two PDE-3 inhibitors in the 
absence of hypothermia and contrast their actions with isoproterenol which is widely used in the 
clinic to suppress J wave syndrome-associated arrhythmias. We avoid using ACh in the 
pharmacologic model so as to exclude the potential anticholinergic effect as a contributor to their 
antiarrhythmic actions.  
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METHODS 
Our ERS models were created using coronary-perfused wedge preparation isolated from 
the hearts of adult mongrel dogs of either sex in conformance with the Guide for Care and Use of 
Laboratory Animals published by the National Institutes of Health (NIH publication No 85-23, 
Revised 1996) and approved by the Institutional Animal Care and Use Committee.  
Arterially perfused left ventricle wedge preparation 
The methods employed were as previously described.
22
 Wedge preparations were excised 
from the lateral (25%) and the inferior wall (75%) of the left ventricle and were perfused via 
distal branches of the left anterior descending artery, left marginal artery or left posterior artery. 
Floating glass microelectrode techniques were used to simultaneously record action potentials 
from two epicardial (Epi1, Epi2) and one endocardial (Endo) site. Together with the action 
potentials, pseudo-ECG was recorded using two AgCl electrodes within the bath positioned 
along the transmural axis of the preparation. The epicardial microelectrodes were used to map 
the epicardial surface of the preparation so as to reveal heterogeneities in depolarization and/or 
repolarization.  
Voltage-clamp measurement of Ito  
Cardiomyocytes were isolated from the epicardium of the canine left ventricle as 
described previously
23
. Ito was measured at 36.5 ºC using whole-cell patch clamp techniques.
4
 Ito 
was evoked using a series of 370 ms voltage steps from -40 mV and +40 mV ms; holding 
potential was maintained at -80 mV and 40 ms prepulse to -20 mV was used to discharge the 
sodium current. Series resistance was compensated ~80% and cells with an Rs values greater 
than 5 MΩ were discarded from analysis. External solutions contained (in mM): 127 NaCl, 4 
KCl, 10 HEPES, 1.8 CaCl2, 1.0 MgCl2, 10 glucose; pH=7.35 with NaOH. The pipette solution 
7 
 
contained (in mM): 125 Potassium aspartate, 10 KCl, 10 NaCl, 1 MgCl2, 10 HEPES, 5 EGTA, 5 
Mg2ATP; pH = 7.2 with KOH. 
AP and ECG parameters were defined and calculated as described in previous studies and briefly 
outlined in the online supplement
12
. 
 
Statistical analysis 
Results are presented as mean ± S.E.M. Statistical analysis was performed using paired Student’s 
t-test  and one-way ANOVA for repeated measurements followed by pairwise comparisons 
corrected using the Holm-Sidak method, as appropriate.  Statistical significance was considered 
at P < 0.05. 
 
RESULTS 
Induction of ERP and VT/VF 
We induced the early repolarization phenotype by adding the transient outward potassium 
current (Ito) agonist NS5806 (7-15 μM) and the calcium channel blocker verapamil (2-3 µM) to 
the coronary perfusate. This led to accentuation of the action potential notch in epicardium but 
not endocardium, thus leading to augmentation of the electrocardiographic J wave secondary to 
amplification of the transmural voltage gradients (Figures 1-3). Increased concentrations of 
provocative agents caused a further increase of J wave area and notch-index (Figures 1-4; Table 
1), leading to all-or-none repolarization at the end of phase 1 of the Epi AP (Figures 1-4). Loss of 
the Epi AP dome at some sites but not others resulted in a prominent increase in epicardial 
dispersion of repolarization (EDR) and transmural dispersion of repolarization (TDR) (Figures 1-
4; Table 1). The voltage gradient between the abbreviated Epi AP and the relatively normal Endo 
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AP produced a prominent ST segment elevation (Figures 1-3). A prominent APD gradient 
developed between sites at which the dome was maintained and where the dome was lost, thus 
creating a vulnerable window within epicardium as well as between epicardium and 
endocardium across the left ventricular wall.  Propagation of the AP dome from regions at which 
it was maintained to regions at which it was lost, caused local re-excitation via a P2R 
mechanism, leading to the development of closely coupled extrasystoles and polymorphic 
VT/VF (Figures 1-3). 
Induction of ERP was observed in all experiments. Table 1 and Figures 4 and 5 show the 
effect of the provocative agents to significantly increase notch-index, J wave area, EDR and 
TDR compared to the controls.  PVT and/or VF developed in 26 of 28 LV wedge preparations, 
compared with 0 of 28 cases under control conditions.  
 
Effects of cilostazol, milrinone and isoproterenol 
Addition of cilostazol (10 μM), milrinone (2.5 μM) or isoproterenol (0.1-1 μM) to the 
coronary perfusate restored the AP dome at all epicardial sites, reduced epicardial and transmural 
dispersion of repolarization, decreased J point and ST segment elevation and terminated all 
arrhythmic activity. Figures 1-3 show representative recordings of APs from LV wedge 
preparations obtained under baseline conditions, after NS5806 (7-15 μM), + verapamil (2-3 µM), 
+ PDE-3 inhibitor (10 µM cilostazol or 2.5 µM milrinone) or the sympathomimetic agent 
isoproterenol (0.1-1 µM) and after washout of the therapeutic compounds. 
 The effects of milrinone, cilostazol and isoproterenol on epicardial AP notch index, J 
wave area, EDR and TDR as well as APD90 values for Epi1, Epi2 and Endo are summarized in 
Figures 4-5 and Table 1. All three agents, by virtue of their action to produce an inward shift of 
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balance of currents, reversed the effect of the provocative agents, restoring all electrophysiologic 
parameters towards normal. Cilostazol (10 µM), milrinone (2.5 µM) and isoproterenol (0.1-1 
µM) restored the AP dome at all epicardial sites, thus reducing notch index, J wave area, as well 
as epicardial and transmural dispersion of repolarization  (Figures 1-5 and Table 1).  
Figures 1-3 illustrates the development of polymorphic VT following exposure to 
NS5806 and verapamil and the effect of cilostazol (10 μM), milrinone (2.5 μM) and 
isoproterenol (0.2 μM) to normalize the ECG and to terminate all arrhythmic activity. Cilostazol 
(10 M) abolished VT/VF in 7 of 8 preparations, whereas milrinone (2.5 M) abolished VT/VF 
in 6 out of 7 preparations, and isoproterenol terminated VT/VF in 7 of 8. In all cases, washout of 
the drug resulted in reappearance of arrhythmic activity (Figures 1-3).  
 
Effect of cilostazol and milrinone on Ito in canine ventricular epicardial myocytes 
We next evaluated the effect of cilostazol and milrinone on Ito in canine left ventricular 
epicardial myocytes using whole cell patch clamp techniques. Macroscopic outward potassium 
current (Ito) was recorded at body temperature from single cardiomyocytes using the whole cell 
patch-clamp technique. Figure 6A shows representative Ito traces recorded under control 
conditions (left, panel) and reduction of the current after addition of cilostazol (10 µM)(right 
panel). Peak Ito was evaluated using a square depolarization pulse to -40 mV to +40 mV applied 
once every 5 seconds. Figure 6B shows the effect of cilostazol (10 µM) on the I-V relationship. 
Cilostazol (10 µM) reduced Ito by 44.4 % at +40 mV (n=6, p<0.02; Figure 6C). Figure 7A shows 
representative Ito traces recorded under control conditions (left, panel) and the reduction of the 
current after addition of milrinone (2.5 µM)(right panel). Figure 7B shows the effect of 
milrinone (2.5 µM) on the I-V relationship. Milrinone (2.5 µM) reduced Ito by 40.4 % at +40 mV 
(n=8, p<0.02; Figure 7C). 
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DISCUSSION and CONCLUSION: 
Our results demonstrate a significant effect of both cilostazol and milrinone to block Ito, 
pointing to this as an important mechanism for their ameliorative effect in ERS, in addition to 
their previously demonstrated effects to augment ICa
24-26
 suggesting that inhibition of Ito may also 
apply to isoproterenol (and other sympathomimetic) in addition to its boosting effect on ICa via 
direct stimulation of the  adrenergic receptors. Future experiments should be directed at a test of 
this hypothesis. It is noteworthy that cilostazol, milrinone and isoproterenol all produce positive 
inotropic and chronotropic effects. The elevation in heart rate would also be expected to 
indirectly decrease Ito because the current is relatively slow to recover form inactivation.  
The much greater potency of milrinone is consistent with the results of previous studies 
reporting that the same concentration of milrinone produces a greater increase in cytosolic cAMP 
than cilostazol.
27, 28
 possibly due to the fact that milrinone blocks both PDE-3 and PDE4.
28
  
It is noteworthy that all of these agents have the potential to enhance not only 
automaticity, but triggered activity as well, and thus may promote extrasystolic activity that may 
have unfavorable outcomes in certain cases.
29
 
Previous reports from our group have provided evidence in support of a preferential 
accentuation of the AP notch in LV epicardium as the basis for ERS.
4, 12
 Accentuation of the 
epicardial AP notch leads to accentuation of transmural gradients across the LV wall and thereby 
the appearance of prominent J point elevation, distinct J waves, or slurring of the descending 
limb of the QRS complex. Consistent with an outward shift in the balance of current, ERS has 
been associated with loss of function mutations in the 1, 2 and 2δ subunits of the cardiac L-
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type calcium channel (CACNA1C, CACNB2, and CACNA2D1) resulting in a reduction in ICa
18, 30
, 
loss of function mutations in sodium channel genes (SCN5A and SCN10A)
21, 31
 causing a 
reduction in INa as well as gain of function mutations in IK-ATP channel genes (KCNJ8 and 
ABCC9) causing an increase in IK-ATP. The J wave syndromes and IVF have also been associated 
with gain of function mutations in the transient outward potassium current (Ito).
17, 32-39
 
In the present study, we pharmacologically modeled the genetic defects and attendant 
ionic changes with the use of verapamil to block ICa and NS5806 to augment Ito.  
NS5806-induced augmentation of Ito sensitized our preparations to the effects of 
verapamil consistent with the association of a higher density of this current in the inferior wall 
with a higher arrhythmic risk.
4
 Addition of verapamil further accentuates the AP notch, leading 
to the development of a more prominent J point and ST segment elevation. Increased 
concentration of these agents can then elicit all-or-none repolarization, leading to loss of the AP 
dome at some epicardial sites but not others, resulting in an epicardial dispersion of 
repolarization (EDR) (Figures 1-5; Table 1). Propagation of the AP dome from sites at which it 
was maintained to sites at which it was lost elicited local re-excitation via a phase 2 reentry 
mechanism within the left ventricular epicardium. Loss of the dome in the epicardium also 
creates a transmural dispersion of repolarization (TDR) giving rise to a vulnerable window 
across the ventricular wall which, when captured by a closely coupled extrasystole generated in 
the epicardium, induces VT/VF (Figures 1-3).  
 Early repolarization syndrome is categorized as a J wave syndrome because like Brugada 
syndrome its electrocardiographic and arrhythmic manifestations are associated with 
accentuation of J waves.
1, 3
 It is therefore no surprise that cilostazol, milrinone and isoproterenol 
have all been found to exert an ameliorative effect in patients with Brugada syndrome and that 
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their mechanisms of action in the setting of Brugada syndrome is similar to their mechanisms of 
action in ERS.
40
 
STUDY LIMITATIONS 
Our pharmacologic models are designed to mimic the genetic defects associated with 
ERS and to test the effects of ameliorative agents. To test the effects of these compounds on 
every single known mutation associated with the J wave syndromes is clearly beyond the scope 
of our (or any) study. Our pharmacological models may not perfectly mimic the effects of every 
mutation, but they do serve to recapitulate the net result of the ion-current imbalance created and 
thus provide a reasonable platform to test the effects of PDE inhibitors and  adrenergic agents.  
While it would be preferable to study the effect of these agents in transgenic animal 
models, none at present are capable of recapitulating the arrhythmic and electrcardiographic 
manifestations of J wave syndromes. In a recent study, Park et al attempted to mimic Brugada 
syndrome phenotype in Yucatan minipigs by heterozygous expression of a nonsense mutation in SCN5A 
(E558X) originally identified in a child with Brugada syndrome.
41
 Myocytes isolated from the 
SCN5A
E558X/+
 pigs showed a loss of function of INa. Various conduction abnormalities were 
observed but not a BrS phenotype, not even after flecainide-test, because pigs lack the transient 
outward current and action potential notch in ventricular cardiomyocytes. These observations 
point to the crucial importance of Ito in the development of J wave syndrome phenotype. 
Transgenic mice are not helpful due to the fundamental differences in repolarization 
characteristics.  
 As with any study involving experimental animal models, extrapolation of the data to the 
clinic must be done with caution. 
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 Clinical perspectives: 
The demonstrated ability of cilostazol and milrinone to inhibit Ito provides support and 
guidance for the development of new drugs for the management of ERS. Although most agents 
used in the treatment of J wave syndromes possess Ito-inhibitory effects (e.g., quinidine, 
cilostazol, bepridil), cardioselective and Ito-specific blockers are not available at present. Further 
investigation designed to address this significant gap in our antiarrhythmic armamentarium is 
urgently needed.  Despite the similarity between canine and human electrophysiology and our 
ability to recapitulate the electrocardiographic and arrhythmic manifestations of ERS in this 
experimental model, translation of our results to humans should be approached with caution.  
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Table 1: Effect of cilostazol, milrinone and isoproterenol on electrophysiological parameters in an 
experimental model of early repolarization syndrome. 
 Notch-
Index 
EDR 
(ms) 
TDR 
(ms) 
J-w-
AUCr 
(mV x 
ms) 
Epi1 
APD90 
(ms) 
Epi2  
APD90 
(ms) 
Endo 
APD90 
(ms) 
Cilostazol        
Control 199.07±44.
9 
16.2±8.2 17.8±4.3 4.3±2.0 203.6±7.
8 
182.8±5.
6 
217.7±5.
1 
NS (7-15 µM) 
+Ver. (2-3µM)  
 
4863.6±669
.4* 
137.9±8.
1* 
111.8±13
.4* 
56.6±12.
2* 
252.2±7.
8† 
109.4±5.
6* 
237.2±14
.3¶ 
+ Cilostazol  
(10µM) 
1041.7±124
.2* 
11.9±3.8
* 
21.3±3.8
* 
15.0±4.0
* 
218.4±7.
5§ 
205.3±4.
4* 
235.6±7.
3¶ 
Washout 
Cilostazol 
4809.8±590
.7* 
123.3±10
.6* 
106.9±11
.2* 
53.0±6.2
* 
252.7±10
.1§ 
121.8±9.
4* 
237.3±11
.5¶ 
Milrinone        
Control 198.2±287 17.3±9.3 17.8±3.8 4.0±2.5 215.7±6.
9 
194.8±5.
9 
227.3±5.
92 
NS  (7-15 µM) 
+Ver. (2-3µM) 
4732.0±764
.8* 
143.0±12
.2* 
110±7.9* 68.4±19.
5* 
250.1±14
.1§ 
104.9±8* 230.1±4.
7¶ 
Milrinone 
(2.5µM) 
1181.8±170
.1* 
3.9±0.7* 11.6±3.7
* 
12.268±1
.5* 
213.3±6.
1¶ 
212.6±6.
6* 
232.6±5.
9¶ 
Washout 
Milrinone 
4668.5±583
.6* 
150.4±15
.1* 
115.6±12
.4* 
51.7±2.6
†  
267.8±10
.7† 
114.2±9.
23* 
243.5±6.
3¶ 
Isoproterenol        
Control 176.8±19.9 13.5±5.6 14.9±5 1.6±0.4 206.5±6.
9 
190.7±5.
9 
213.4±4.
9 
NS  (7-15 µM) 
+Ver. (2-3 µM)  
4114.7±400
.8* 
123.9±11
.9* 
88.9±5.2
* 
46.0.0±4.
9.* 
234.5±12
¶ 
111.2±9.
3* 
198.5±6.
3¶ 
+Iso.  (1µM) 406.9±65.6
* 
5.9±1.6* 13.6±4* 7.8±2.7* 164.1±8.
3* 
158.6±7.
7* 
179.±7.8
¶ 
Washout Iso 3628.6.±79
5.9* 
87.7±25.
4* 
67.1±15.
0* 
39.5±8.2
* 
207.9±22
.6¶ 
116.0±14
.3§ 
195.4±11
.5¶ 
NS=NS5806; Ver.=Verapamil; Iso=Isoproterenol; J-w-AUCr=J wave area (normalized) 
 Data are presented as mean ± SEM; * P=<0.001; † P=<0.004; §: P<0.05; ¶ P>0.05. 
 n=7 for cilostazol, n=6 for milrinone, n=7 for isoproterenol(Epi1 represents the longer, Epi2 the shorter 
epicardial APD90) 
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Figure 1: Ameliorative effect of cilostazol (10µM) in an arterially perfused canine left 
ventricular model of early repolarization syndrome. Each panel shows simultaneously recorded 
epicardial (Epi1, Epi2) and endocardial (Endo) action potentials, together with a pseudo-ECG.  
A: Control. B: Recorded 20 min and 30 min after addition of verapamil (2 μM) and NS5806 (7 
μM) to the coronary perfusate. C: 15 minutes after addition of 10 M cilostazol to the coronary 
perfusate. D: Recorded 15 min after withdrawal of cilostazol. 
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Figure 2: Ameliorative effect of milrinone (2.5µM) in an arterially perfused canine left 
ventricular model of early repolarization syndrome. Each panel shows simultaneously recorded 
epicardial (Epi1, Epi2) and endocardial (Endo) action potentials, together with a pseudo-ECG.  
A: Control. B: Traces recorded 40 min after the addition of Ca
2+
-channel blocker
 
verapamil 
(2µM) and Ito-agonist NS5806 (7 µM). C: 15 minutes after raising NS5806 concentration to 12 
µM. D: 10 minutes after addition of milrinone 2.5µM to the coronary perfusate. E: 20 minutes 
after the discontinuation of milrinone infusion.  F: 20 seconds later.  
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Figure 3: Ameliorative effects of isoproterenol (0.2 µM) in an arterially perfused canine left 
ventricular model of early repolarization syndrome. Simultaneously recorded epicardial (Epi1, 
Epi2) and endocardial (Endo) action potentials, together with pseudo-ECG positioned in the 
transmural axis. A: Control. B: 20 min after addition of the Ito agonist NS5806 (12µM) to the 
coronary perfusate. C: After 16 min exposure to verapamil (2µM), in addition to NS5806 
(12µM).D: 3 minutes later.  E: 5 min after the start of isoproterenol (0.2µM) infusion. F: 5 min 
after the discontinuation of isoproterenol infusion. 
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 Figure 4: Notch-index (left) and normalized J wave area (right) at each experimental step.  
In each panel: a. Control; b. Recorded after application of the Ito agonist NS5806 and ICa 
antagonist verapamil; c. Recorded after addition of cilostazol 10µM (top row), milrinone 2.5µM 
(middle row), or isoproterenol 1µM (bottom row);  d. Recorded after wash-out of drugs. Data are 
presented as mean ± SEM.. Significance is shown relative to previous treatment: * P=<0.001; 
†P=<0.004.  (n = 7 for cilostazol; n = 6 for milrinone; n = 7 for isoproterenol). 
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Figure 5: Epicardial (EDR, left) and transmural (TDR, right) dispersion of repolarization at 
each experimental step. In each panel: a. Control; b. Recorded after application of the Ito agonist 
NS5806 and ICa antagonist verapamil; c. Recorded after addition of cilostazol 10µM (top row), 
milrinone 2.5µM (middle row), or isoproterenol 1µM (bottom row);  d. Recorded after wash-out 
of drugs. Data are presented as mean ± SEM.. Significance is shown relative to previous 
treatment:  * P=<0.001 (n = 7 for cilostazol; n = 6 for milrinone; n = 7 for isoproterenol). 
25 
 
 
Figure 6: Cilostazol inhibition of transient outward potassium current (Ito). A. Representative 
macroscopic Ito current traces for control and cilostazol (10 µM). B. Current-Voltage (I-V) 
relationship for Ito density in control and in response to 10 µM cilostazol (n=6 for each). C. Bar 
graph showing Ito at following a step to 20 and 40 mV in presence and absence of cilostazol (10 
µM).  Mean ± SEM. 
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Figure 7: Milrinone inhibition of transient outward potassium current (Ito). A. Representative 
macroscopic Ito current traces for control and milrinone (2.5 µM). B. Current-Voltage (I-V) 
relationship for Ito density in control and in response to 2.5 µM milrinone (n=8 for each). C. Bar 
graph showing Ito at following a step to 20 and 40 mV in presence and absence of milrinone (2.5 
µM).  Mean ± SEM. 
 
